Evaluating Harmony Biosciences: Insights From 8 Financial Analysts
Evaluating Harmony Biosciences: Insights From 8 Financial Analysts
评估和谐生物科学：来自8位金融分析师的见解
Harmony Biosciences (NASDAQ:HRMY) underwent analysis by 8 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
和谐生物科学（纳斯达克股票代码：HRMY）在上个季度接受了8位分析师的分析，揭示了从看涨到看跌的一系列观点。
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
下表简要介绍了他们最近的收视率，展示了过去30天中不断变化的情绪，并将其与前几个月进行了比较。
Insights from analysts' 12-month price targets are revealed, presenting an average target of $42.62, a high estimate of $53.00, and a low estimate of $28.00. This current average reflects an increase of 11.42% from the previous average price target of $38.25.
分析师12个月目标股价的见解已经公布，平均目标股价为42.62美元，最高估计为53.00美元，低估值为28.00美元。目前的平均价格比之前的平均目标价38.25美元增长了11.42％。
Breaking Down Analyst Ratings: A Detailed Examination
分解分析师评级：详细审查
In examining recent analyst actions, we gain insights into how...
在研究分析师最近的行...
登录免费看全文
登录/注册